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Abstract
The majority of patients with spinal muscular atrophy (SMA) identified to date harbor
a biallelic exonic deletion of SMN1. However, there have been reports of SMA-like
disorders that are independent of SMN1, including those due to pathogenic variants
in the glycyl-tRNA synthetase gene (GARS1). We report three unrelated patients with
de novo variants in GARS1 that are associated with infantile-onset SMA (iSMA).
Patients were ascertained during inpatient hospital evaluations for complications of
neuropathy. Evaluations were completed as indicated for clinical care and manage-
ment and informed consent for publication was obtained. One newly identified,
disease-associated GARS1 variant, identified in two out of three patients, was ana-
lyzed by functional studies in yeast complementation assays. Genomic analyses by
exome and/or gene panel and SMN1 copy number analysis of three patients identi-
fied two previously undescribed de novo missense variants in GARS1 and excluded
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SMN1 as the causative gene. Functional studies in yeast revealed that one of the de
novo GARS1 variants results in a loss-of-function effect, consistent with other patho-
genic GARS1 alleles. In sum, the patients' clinical presentation, assessments of previ-
ously identified GARS1 variants and functional assays in yeast suggest that the
GARS1 variants described here cause iSMA. GARS1 variants have been previously
associated with Charcot–Marie–Tooth disease (CMT2D) and distal SMA type V
(dSMAV). Our findings expand the allelic heterogeneity of GARS-associated disease
and support that severe early-onset SMA can be caused by variants in this gene. Dis-
tinguishing the SMA phenotype caused by SMN1 variants from that due to patho-
genic variants in other genes such as GARS1 significantly alters approaches to
treatment.
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1 | INTRODUCTION
Spinal muscular atrophy (SMA) and Charcot–Marie-Tooth (CMT) disease
are hereditary neuromuscular disorders that lead to progressive
weakness and muscle wasting. CMT disease refers to a group of disor-
ders characterized by a progressive chronic motor and sensory poly-
neuropathy. CMT2, specifically Charcot–Marie–Tooth disease 2D
(CMT2D), is the sub-type associated with variants in the glycyl-RNA syn-
thetase gene, GARS1 (also referred to as GARS, which we use throughout
the manuscript). CMT2D typically presents with muscle weakness of the
hands, characterized by distal motor and sensory neuropathy.
The SMA group of disorders are typically characterized by sym-
metric proximal muscle weakness and atrophy resulting from progres-
sive degeneration and loss of anterior horn cells in the spinal cord and
the brain stem nuclei. The first SMA patients (Russman, 2007) were
diagnosed based on clinical and histopathological features. Unified
inclusion criteria for SMA were developed by the International SMA
Consortium (Munsat, 1991). Patients were stratified by severity based
on criteria including clinical features, age of onset and age at death
(Drew, Blair, & Nicholson, 2011).
In contrast to the extreme allelic and locus heterogeneity
observed in CMT (Timmerman, Strickland, & Züchner, 2014), the vast
majority of patients with SMA harbor a biallelic exonic deletion of
SMN1 mapping to the long arm of chromosome 5. There has been
increasing appreciation of non-SMN1 forms of SMA since the initial
reports where it has been estimated that about 5% of SMA patients
have a genetic etiology other than SMN1 (Wirth et al., 1999). Over
15 loci have been associated with clinical presentations that mimic
SMN1-related SMA. These non-SMN1 SMAs are sometimes referred
to as non-5q SMA and typically affect the proximal muscles. On the
severe end of the spectrum within the non-5q SMA subgroup is SMA
with respiratory distress (SMARD), due to biallelic pathogenic variants
in IGHMBP2 (Grohmann et al., 2001; Guenther et al., 2007). Yet
another subgroup, SMA type V distal type (dSMAV), presents with
distal weakness and no sensory involvement. Both CMT2D and
dSMAV are caused by heterozygosity for pathogenic variants in GARS
gene, encoding glycyl-tRNA synthetase. In fact, recent literature sug-
gests that dSMAV and CMT2D are on a clinical spectrum of GARS-
associated axonal neuropathy, not distinct diseases (Antonellis,
Goldfarb, & Sivakumar, 1993). In addition, multiple case reports have
described patients with a pathogenic variant in GARS with an iSMA
like phenotype (Eskuri, Stanley, Moore, & Mathews, 2012; James
et al., 2006; Liao et al., 2015).
In humans, there are 37 genes encoding aminoacyl-tRNA synthe-
tases (aaRS) (Antonellis & Green, 2008). Variants in genes encoding
aaRSs have been associated with various human diseases including
early onset, multi-system recessive phenotypes and dominant periph-
eral neuropathy (Fuchs et al., 2019; Meyer-Schuman & Antonellis,
2017). Over the past 16 years, multiple studies have associated
defects in aaRS with CMT (Storkebaum, 2016) and dSMAV (Tsai
et al., 2017).
The GARS gene was the first aaRS to be implicated in a human
inherited disease (Antonellis et al., 2003, 1993). GARS is critical for
charging glycine onto cognate tRNA molecules and is required for pro-
tein synthesis in the mitochondria and the cytosol (Chihara,
Luginbuhl, & Luo, 2007; Qin et al., 2014). The human GARS protein
consists of a N-terminal WHEP-TRS domain, a catalytic domain inter-
spersed by three insertion domains and a C-terminal anticodon-
binding domain (Antonellis et al., 2003; Qin et al., 2014). The majority
of patients reported with GARS-associated dominant neuropathy pre-
sent with later onset CMT2D or dSMAV (Antonellis et al., 2003). Here
we present three patients with severe, early-onset SMA. Each patient
carries a de novo pathogenic variant in either the catalytic or antico-
don binding domain of GARS. Analysis of these results indicates that
pathogenic variants in the anticodon binding and the catalytic
domains can result in an early-onset form of SMA.
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2 | PATIENTS AND METHODS
Patients were ascertained in the course of routine clinical care pro-
vided at three institutions. Genetic testing, imaging, neurophysiology,
and histopathology studies were done on a clinical basis.
Yeast complementation assays were performed as previously
described (Oprescu et al., 2017). The p.Ile334Asn GARS variant was
modeled in the human wild-type GARS ΔMTSΔWHEP open-reading
frame (Chien et al., 2014; Oprescu et al., 2017). Mutagenesis was per-
formed using the Quickchange II XL Site-Directed Mutagenesis Kit, a
sequence-validated wild-type GARS ΔMTSΔWHEP pDONR221 con-
struct, and mutation-specific primers (available upon request). Reac-
tions were transformed into Escherichia coli, and plasmid DNA was
purified from individual colonies and sequenced to confirm the pres-
ence of the mutation and the absence of PCR-induced errors.
Sequence-validated constructs for wild-type and p.Ile334Asn GARS
ΔMTSΔWHEP were cloned into pYY1 (Chien et al., 2014) using Gate-
way cloning technology (Invitrogen). The resulting reactions were
transformed into E. coli, and plasmid DNA was purified from individual
colonies and digested with BsrGI to confirm proper recombination. To
assess the ability of wild-type and p.Ile334Asn GARS ΔMTSΔWHEP
to support cellular growth, a previously validated haploid yeast strain
with the endogenous GRS1 locus deleted and viability maintained via
a pRS316 vector bearing wild-type GRS1 (Turner, Lovato, & Schimmel,
2000) was transformed with wild-type GARS ΔMTSΔWHEP, p.Ile334-
Asn GARS ΔMTSΔWHEP, or the pYY1 vector with no GARS insert.
Transformed yeast cells were grown on solid media lacking leucine
(pYY1 harbors the LEU2 gene) and uracil (pRS316 harbors the URA3
gene). Colonies were grown to saturation in 2 mL -leu-ura liquid
medium at 30C and 275 rpm for 48 hr. A 1 mL aliquot from each
2 mL culture was spun down at 10,000 rpm and re-suspended in
50 μL UltraPure RNase/DNase-free water. Undiluted cultures and
dilutions of 1:10 and 1:100 were spotted on 0.1% 5-FOA complete
solid medium (Teknova, Hollister, CA) to select for cells that have
spontaneously lost the URA3-bearing maintenance vector (Boeke,
Trueheart, Natsoulis, & Fink, 1987). Yeast viability was assessed by
visual inspection after 5 days of incubation at 30C. Two colonies per
transformation were assayed.
3 | RESULTS
3.1 | Clinical features of patients
We identified three patients with de novo variants in the GARS gene
that led to very early onset neuropathy with respiratory distress, mim-
icking iSMA. Clinical features of these patients are summarized in
Table 1.
Patient 1 is a former appropriate-for-age (AGA) 40w4d male, born
by spontaneous vaginal delivery to a 29-year-old Hispanic female and
a 28-year-old Hispanic male. The pregnancy was notable for
oligohydramnios with no associated complications. The parents were
non-consanguineous and the family history was negative for
neuropathy. At birth, the patient had subtle decreased movement in
his lower extremities compared to his upper extremities, but without
notable hypotonia, respiratory distress, or feeding difficulties.
At approximately 9 weeks of age, he was hospitalized due to
respiratory distress, decreased movements, and poor feeding. Initial
physical exam findings were significant for an alert infant with a weak
cry and associated cyanosis. He progressed to respiratory failure
requiring mechanical ventilation. His motor exam was significant for
generalized hypotonia with antigravity strength in the upper extremi-
ties and inability to overcome gravity in the lower extremities. Proxi-
mal muscles were weaker than distal muscles. Muscle stretch reflexes
were absent. Tongue fasciculations were present. There was no obvi-
ous clinical evidence of sensory impairment, although detailed sensory
exam was limited due to his young age and sedation. At 11 months of
age, he remains alert, on 24-h chronic ventilation and gastrostomy
tube, and requires assistance for all activities of daily living.
His diagnostic evaluation was suggestive of motor neuron
involvement in many aspects. MRI of his complete spine showed mar-
ked volume loss of ventral cauda equina as well as atrophy of lower
lumbar and sacral paraspinal musculature, gluteal and iliopsoas mus-
cles, and pelvic girdle muscles (Figure 1a–c). On nerve conduction
study, compound muscle action potentials had severely decreased
amplitude with normal latency while some muscles were non-
responsive. Sensory nerve action potentials were normal except his
right sural nerve that was nonresponsive and bilateral medial plantar
nerves that showed mildly prolonged latencies with the decreased
amplitude on the right compared to the left. Needle EMG showed
decreased insertional activity and recruitment in all tested muscles.
Some muscles showed large amplitude motor unit potential, and one
muscle with severely decreased recruitment showed polyphasic activ-
ity. Biopsy of his quadriceps muscle had marked variation in fiber size
with small group and fascicular atrophy (Figure 1d).
Patient 2 was born to his Hispanic mother and father at 39 weeks
gestation via a repeat C-section. His weight was appropriate for ges-
tational age at 7 pounds. His mother had an uncomplicated pregnancy
and he was discharged on day of life 4 without any detected medical
issues. There was no consanguinity and no family history of any neu-
romuscular disorders.
At 6 weeks of age he began having repeated events of respiratory
failure requiring multiple intubations and ultimately a tracheostomy
~2 months of age. He has remained on constant mechanical ventila-
tion since that time. His chest X-rays consistently revealed right hemi-
diaphragm elevation (Figure 1e). At 4 months of age he had an ultra-
sound evaluation revealing minimal movement of the right hemi-
diaphragm representing likely diaphragmatic paralysis versus signifi-
cant paresis. A subsequent ultrasound at 9 months of age revealed
apparent diminished diaphragmatic motion bilaterally.
He was first evaluated by neurology at 9.5 months of age due to
progressive weakness, distal greater than proximal, and respiratory
failure. He had significant generalized weakness including lack of anti-
gravity strength proximally and nearly no movement distally. At that
time, he had no fixed contractures but hands had claw-like appear-
ance suggestive of significant intrinsic muscle atrophy and bilateral
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caval deformity of his feet. Reflexes were absent throughout. There
were no overt fasciculations. There was no evidence of sensory defi-
cits on clinical exam. He has always been very alert and with appar-
ently normal cognitive function.
He was initially able to roll over around 3 months of age but lost
this skill at 18 months of age. He attained the ability to sit at
12 months of age and maintained this at last follow up at 39 months
of age but is unable to attain this posture independently.
F IGURE 1 (a) Patient 1 MRI of
the spine in sagittal view. Note
marked volume loss of ventral cauda
equina (white arrowhead) and intact
dorsal cauda equina (black
arrowhead). White arrows signify the
spinal level of images (b) and (c) that
show marked volume loss of ventral
cauda equina (white arrowhead) and
intact dorsal cauda equine (black
arrowhead) in axial view. (d) Patient
1, hemotoxylin and eosin stain of
quadriceps muscle with marked
variation in fiber size with small group
and fascicular atrophy typical of
SMA1; (e) Patient 2, chest X-ray with
elevation of Right hemi-diaaphragm;
(f) Patient 2, hemotoxylin and eosin
stain of muscle with variation in
muscle size, rare myophagocytosis,
regenerating fibers (g), (h), and
(i) Patient 3, muscle ultrasound with
severe atrophy and neurogenic
changes of distal > proximal muscles
[Color figure can be viewed at
wileyonlinelibrary.com]
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At 39 months of age he remained unable to perform antigravity move-
ments proximally and had very little distal movements. He had signifi-
cant ankle contractures and has had surgery for his progressive
kyphoscoliosis.
His evaluation has included a MRI of the brain and C-spine com-
pleted at 9 months of age which revealed slightly increased prominence
of the bi-frontal and temporal subarachnoid spaces and mild promi-
nence of the lateral and third ventricles. The cervical spine MRI was
normal. At 10 months of age he had a left thigh muscle biopsy with fea-
tures of denervation atrophy with group atrophy with large groups of
atrophic fibers (both type 1 and 2 fibers) as well as features of chronic
active myopathy (variation in muscle size, rare myophagocytosis, reg-
enerating fibers, marked endomysial fibrosis, occasional darkly stained
hyalinized fibers on trichrome stain, indistinct fiber typing on ATPase
pH 9.4, and co-expression of fast and slow myosin) (Figure 1f).
An EMG/NCV was performed at 3 years of age which revealed a
severe, active, diffuse, axonal sensory-motor but predominantly motor
peripheral neuropathy. Compound muscle action potentials were
absent in all tested nerves (right peroneal, tibial, median, ulnar, and
musculocutaneous nerves). Sensory nerve action potentials were nor-
mal in the median and ulnar nerves but absent in the right medial
plantar and sural nerves. Needle EMG revealed numerous fibrillation
potentials, complex repetitive discharges, and increased insertional
activity. There were a few fasciculation potentials. Activation was
examined in a few muscles, which revealed long duration and high
amplitude motor units with reduced recruitment.
Patient 3 was the AGA product of a 38-week gestation delivered
by spontaneous vaginal delivery to a Caucasian father and French
Canadian mother. There was no consanguinity. Pregnancy was
uncomplicated and with normal perceived fetal movement. Apgar
scores were 8 and 9 at 1 and 5 min, respectively. Inspiratory stridor
and hypotonia were noted at birth. He was subsequently diagnosed
with vocal cord paralysis. By 1 month of age, he was having difficulty
maintaining weight, largely due to poor suck, swallowing difficulties
and early fatigue with feeding. He developed more notable respiratory
insufficiency at 10 weeks, also with bulbar weakness, including dro-
oling. BiPAP was trialed but following an acute GI bleed he was
intubated and subsequently failed multiple extubation attempts. He
underwent tracheostomy at 4 months of age and remains ventilator
dependent. He had progressive weakness of his extremities, initially
with distal weakness that progressed to proximal involvement. At
5 months, he was able to move his legs and at 7 months of age he
was still able to move his arms; however, he subsequently lost those
abilities. At the time of his last examination, at 14 months of age, he
was alert and attentive to his surroundings with marked weakness. He
was able to move his shoulders within the plane of gravity, and facial
strength was relatively preserved. Tongue movements were limited
and he had notable tongue fasciculations.
TABLE 1 Clinical features of three patients with de novo GARS variants and infantile SMA presentation with respiratory distress
Patient 1 Patient 2 Patient 3
Pathogenic variant c.1001T>A (p.Ile334Asn) c.1001T>A (p.Ile334Asn) c.1954G>C (p.Gly652Arg)
Inheritance de novo de novo de novo
Age of presentation 9 weeks 6 weeks Day 0
Age at most recent encounter 6 months 39 months 14 months
Initial presentation of respiratory distress, poor
feeding and muscle weakness
+ + +
Neurologic
Hypotonia, lower extremities > upper extremities + + +
Fasciculations + − +
Hyporeflexia + + +
Atrophy − + +
Pes Cavus − + −
Contractures − + +
Sensory impairment a + −
Respiratory
Stridor + + +
Weak cry + + +
Elevated right diaphragm + + b
Chronic ventilation + + +
Feeding/nutrition
Poor feeding + + +
G-tube dependent + + +
aAbsence of sural nerve response.
bPoor diaphragm movement noted on ultrasound.
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His evaluation included multiple EMGs, brain MRI and muscle
ultrasound. His brain MRI was largely normal. Muscle ultrasound at
13 months of age showed severe atrophy and neurogenic changes in
all muscles, more pronounced distally than proximally (Figure 1g–i). In
the distal lower extremity, there are dense and severely atrophic mus-
cles with no voluntary or spontaneous activity seen. Triceps were rel-
atively spared compared to the biceps and deltoid muscles, but all
showed abnormal echogenicity. There were fasciculations seen in the
proximal upper extremities, paraspinal muscles, tongue, and orbicularis
oris muscle. The diaphragm muscle appeared very thin and with no
spontaneous movement visualized.
Patient 3 had multiple EMGs. His initial EMG was at 2 months of
age, which showed a length-dependent, severe, mixed axonal and
demyelinating predominantly motor sensorimotor polyneuropathy
with active denervation seen on needle EMG exam in proximal and
distal muscles of the upper and lower extremities. Repeat EMG at
3 months of age showed absent sensory responses, absent motor
responses in the lower extremities, markedly reduced median CMAP
motor amplitude (0.6 mV), and needle EMG exam again showed
abnormal spontaneous activity suggesting active denervation. Repeat
EMG at 13 months of age showed absent sensory and motor
responses, no voluntary motor units elicited on needle EMG distally,
F IGURE 2 (a) The mutation
spectrum of GARS. Missense
mutations causing CMT2D/ dSMA
are shown on the GARS primary
structure. The domains are colored as
indicated. (b) Conservation of the p.
Ile334 and the p.Gly652 residues.
(c) The p.Ile334Asn GARS variant
causes a loss-of-function effect in
yeast complementation assays. Yeast
lacking endogenous GRS1 (the yeast
ortholog of GARS) were transformed
with vectors containing wild-type
GARS ΔMTSΔWHEP or p.Ile334Asn
GARS ΔMTSΔWHEP, or a vector
with no GARS insert (“Empty”).
Resulting cultures were plated
undiluted or diluted (1:10 or 1:100)
on media containing 5-FOA or media
lacking leucine and uracil (−leu-ura)
and grown at 30C. Two
independently generated mutant
constructs (“a” and “b”) were tested
[Color figure can be viewed at
wileyonlinelibrary.com]
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and evidence of ongoing active denervation in the proximal upper
extremity (biceps brachii muscle).
3.2 | Variants in the catalaytic and anticodon
binding domain of GARS leads to early onset SMA
None of the three patients described above harbored the SMN1 gene
deletion. Trio exome sequencing of Patient 1 and a hereditary neurop-
athy gene panel testing of Patient 2 revealed heterozygosity for the
same NM_002047.2:c.1001T>A (p.Ile334Asn) missense variant in the
catalytic domain of GARS (Figure 2a). This was consistent with the
overlapping clinical presentation of the two patients (Table 1). This
variant, absent from the gnomAD variant database (Karczewski et al.,
2019), affects a highly conserved residue that is invariant from yeast
to humans (Figure 2b). The variant identified in both of these patients
was a de novo event. Consistent with the involvement of this residue
of GARS in hereditary neuropathy, a different missense substitution at
this codon (p.Ile334Phe, also reported as p.Ile280Phe) has been iden-
tified in patients with features of later onset dSMA (James et al.,
2006; Klein et al., 2014). Additionally experimental studies show that
this residue is critical for charging tRNA with glycine in vitro
(Antonellis et al., 2006; Griffin et al., 2014). Consistent with this we
also found that the p.Ile334Asn variant failed to complement the dele-
tion of the yeast ortholog GRS1 in a yeast complementation assay,
indicating a loss-of-function effect consistent with other neuropathy-
associated GARS variants (Griffin et al., 2014) (Figure 2c).
Trio exome sequencing in Patient 3 revealed heterozygosity for a
de novo—and previously unreported- c.1954G>C (p.Gly652Arg) GARS
variant. The c.1954G>C (p.Gly652Arg) change is also not present in
the gnomAD database; however a p.Gly652Glu variant is present in
1 out of 249,522 alleles. The affected Gly652 residue is conserved
between the nematode Caenorhabditis elegans to humans (Figure 2b).
Additionally, a different change of the same amino acid (p.Gly652Ala)
has been previously reported to cause infantile or early childhood
onset axonal CMT and distal spinal muscular atrophy type (Eskuri
et al., 2012; James et al., 2006). The p.Gly652Ala change is within the
anticodon-binding domain of GARS and mutations within the
anticodon-binding domain have been proposed to be more damaging
to enzyme function than those within other GARS domains. Taken
F IGURE 3 (a) The majority of
patients with GARS variants exhibit
late-onset clinical features of
neuropathy. Plot of age of onset
(years) versus amino acid residue for
different variants in GARS implicated
in different types of neuropathy. The
variants reported in this study are
indicated by arrows. (b) Age of onset
(years) and published diagnosis of
patients with putative GARS
pathogenic variants. Age of onset is
on the y axis and each facet
represent the domains of GARS. Each
of the rectangles depicts patients and
their published diagnosis. Majority of
patients are diagnosed as dSMAV or
CMT2D. iSMA: infantile SMA [Color
figure can be viewed at
wileyonlinelibrary.com]
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together we identified two potentially deleterious de novo variants in
GARS in three patients presenting with infantile onset SMA.
3.3 | The I334N GARS variant does not support
yeast cell growth in complementation assays
Yeast complementation assays have revealed loss-of-function charac-
teristics for the majority of CMT-associated GARS variants (Antonellis
et al., 2006; Griffin et al., 2014) indicating that this model can be
employed to predict pathogenicity (Oprescu et al., 2017). GARS with
both the mitochondrial targeting sequence (MTS) and WHEP domain
deleted (ΔMTSΔWHEP) has been shown to allow robust cell growth
(Chien et al., 2014; Oprescu et al., 2017). We therefore compared the
ability of wild-type and p.Ile334Asn human GARS ΔMTSΔWHEP to
complement the loss of endogenous yeast GRS1 (the yeast ortholog
of GARS). Complementation studies were performed in a previously
validated haploid yeast strain deleted for endogenous GRS1 and
maintained with GRS1 on a URA3-bearing vector (Turner et al., 2000).
Wild-type or p.Ile334Asn GARS ΔMTSΔWHEP expression constructs,
or constructs with no GARS insert (“Empty” in Figure 2c) were trans-
formed into the yeast strain and grown on 5-FOA, which selects for
spontaneous loss of the URA3-bearing maintenance vector (Figure 2c).
The empty plasmid did not support yeast growth, consistent with GRS1
being an essential gene (Figure 2c). The wild-type GARS ΔMTSΔWHEP
expression construct supported robust yeast growth, which indicates
that human GARS can complement the loss of the endogenous GRS1
locus, consistent with previous findings (Chien et al., 2014; Oprescu
et al., 2017). The p.Ile334Asn GARS ΔMTSΔWHEP expression con-
struct was unable to support yeast growth (Figure 2c), suggesting that
p.Ile334Asn GARS represents a loss-of-function allele.
3.4 | De novo variants in the GARS anticodon
binding domain leads to early-onset SMA
The observation of three patients with de novo variants in different
functional domains of GARS and clinical features consistent with
early-onset SMA suggested that depending on the nature of the
amino-acid change and location of the variant in the GARS protein,
the presentation of a patient may mimic infantile onset SMA rather
than a later onset CMT2D or dSMAV. Among the patients with dSMA,
CMT2D, or infantile SMA and GARS variants published in the litera-
ture (n = 45), we found that seven had infantile onset of symptoms
(15.5%, age of onset less than 2 years old, Figure 3a,b). The majority
of patients are diagnosed with dSMA or CMT2D, particularly when
the variants are not in the anticodon-binding or catalytic domain
(Chung et al., 2018; Eskuri et al., 2012; James et al., 2006; Liao et al.,
2015) (Figure 3b). Our identification of three patients with early-onset
SMA adds to the growing appreciation of the broad spectrum of dom-
inant phenotypes associated with GARS pathogenic variants. This
includes early onset motor neuropathy that may mimic infantile SMA
with respiratory distress, as seen in our patients.
The p.Ile334Asn and p.Gly652Arg GARS variants affect amino
acids that are located in the catalytic and the anticodon binding
domains of GARS, respectively. Both of these residues with a differ-
ent amino-acid change were previously reported in patients
(Antonellis et al., 2003; Eskuri et al., 2012; James et al., 2006) pre-
senting with neuropathic clinical features. An isoleucine to phenylala-
nine change at position 334 has been associated with a later onset
dSMA in three patients (James et al., 2006; Figure 3a). The isoleucine
to asparagine amino-acid change is the first amino acid in this domain
that has been associated with early-onset SMA. In contrast, the
change from glycine at position 652 to another hydrophobic residue,
alanine, has been reported in three patients with early-onset SMA like
features. Consistent with the critical nature of this glycine residue, we
found that a patient with a hydrophobic to polar amino-acid change
(p.Gly652Arg) at this residue presented with early-onset SMA with
respiratory distress.
4 | DISCUSSION
We report three patients with infantile-onset SMA due to pathogenic
variants in GARS. This expands the number of patients with GARS-
associated, infantile-onset SMA adding support to the idea that dele-
terious mutations in GARS can lead to infantile SMA. The clinical pre-
sentations of patients with pathogenic GARS variants were very
similar to that observed in patients with deletion of SMN1. Indeed, in
six out of the 10 cases of infantile-onset SMA due to GARS variants,
SMN1 testing was ordered as the first line of genetic testing. Given
the overlap of clinical features we suggest that in the absence of a
homozygous deletion in SMN1, consideration should be given for a
compound heterozygous state, as approximately 5% of patients with
SMA will have a deletion in one allele and a point mutation in the
other. If this were not to identify an etiology, then further genetic
analysis should proceed with either a comprehensive neuromuscular
panel or whole exome/genome analysis. Based on currently available
commercial gene panels, GARS is most often included in those tests
targeted at CMT or distal hereditary neuropathies with later rather
than early onset. Therefore, the diagnosis of GARS-related disease in
patients with infantile onset may be missed. With the addition of
SMN1 dosage testing to newborn screening in many states, second-
line testing with whole exome sequencing can be expediated in those
patients in which SMN1-related disease has already been excluded.
Our patients' clinical presentations overlap with both SMA and
SMA-related disorders. There is overlap with SMA type 1, due to early
onset, and dSMAV due to distal weakness greater than proximal. In
addition, our patients had varying degrees of sensory impairment,
which can be found in CMT2D, a disorder known to overlap with
dSMAV. Finally, due to distal greater than proximal weakness and initial
presentation of respiratory distress, our patients fit a diagnosis of
SMARD1. We highlight the dilemma of diagnosis for our patients that
the clinically defined boundaries between these syndromes are not as
impermeable as previously thought, consistent with recent literature
(Darras, 2011; Peeters, Chamova, & Jordanova, 2014). As we transition
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from diagnoses hinged purely on clinical features to those based on
underlying genomic alterations, these classifications will likely become
further refined. For example, to our knowledge IGHMBP2 is the only
gene associated with SMARD1; however, based on this report, certain
GARS variants may lead to SMARD1-like features. This could poten-
tially alter the current diagnostic criteria for SMARD1, which include
pathogenic variants in IGHMBP2.
GARS has been associated with CMT2D and dSMA. Consistent
with recent reports (Chung et al., 2018; Eskuri et al., 2012; James et al.,
2006; Liao et al., 2015), our results suggest that GARS variants could
potentially lead to early onset SMA-like features depending on the
nature and location of the amino acid change. Functional studies have
shown that GARS consists of multiple domains including the catalytic,
anti-codon binding and dimerization domain, and mutations in each of
these domains (Antonellis et al., 2003; Griffin et al., 2014) leads to axo-
nal neuropathy. Several disease mechanisms have been proposed
based on mice and in vitro studies. Indeed it was recently shown that
defective sensory motor connectivity in spinal muscular atrophy results
from dysregulation of GARS pathway. This in turn may contribute to
molecular and phenotypic overlap between spinal muscular atrophy
and CMT2D. (Shorrock et al., 2018). The isoleucine to asparagine vari-
ant in our patients is located in the catalytic core of GARS. The critical
nature of this residue is evident from functional studies in yeast. An
isoleucine to phenylalanine change in this residue resulted in less than
10% aminoacylation activity compared to the wild-type GARS but was
able to maintain yeast viability when modeled in the yeast ortholog
GRS1 (Griffin et al., 2014). In contrast, the isoleucine to asparagine
change that we identified in our patients with a more severe clinical
presentation results in a loss-of-function effect in yeast complementa-
tion assays. It is therefore likely that the p.Ile334Asn variant in GARS
results in reduced enzyme function, which may be particularly detri-
mental to neurons. The second variant we identified (p.Gly652Arg)
affects an amino acid in the anticiodon binding domain. Another variant
affecting the same codon, p.Gly652Ala, also found in patients with
severe early-onset SMA-like features did not differ from wild-type in a
yeast complementation assay (Stum et al., 2011) but was shown to
aberrantly interact with proteins involved in axonal transport (Mo et al.,
2018). Our finding of a novel variant at the same residue in a patient
with severe early-onset SMA supports the idea that depending on the
affected domain, different GARS alleles cause axonal neuropathy
through different mechanisms that are likely not captured in the yeast
assays. These findings continue to expand the spectrum of clinical phe-
notypes of “GARS-Associated Axonal Neuropathy”. Studies are needed
to elucidate the precise mechanisms of how these newly identified var-
iants in GARS lead to axonal neuropathy.
Despite the potential pitfalls of differentiating the different types
of SMA-related diseases, due to recent development of treatment for
SMN1-related diseases, the differentiation at the genomic level has
important management implications. The recent development of anti-
sense oligonucleotide therapy for SMN1-related disease has altered
the outcome, especially when given to children early in the disease
course. However, since the antisense oligonucleotide and more
recently adenovector-based gene therapy are the only therapeutics for
SMN1-related disease, it is crucial to delineate SMN1 spinal muscular
atrophy from the less common, yet more genetically diverse, non-5q
SMA. Specifically, it is important that physicians are aware that non-5q
SMA can present as a severe, infantile phenotype, as was the case with
our patients. Our results suggests tRNA ligases particularly GARS1 as a
key contributor to clinical presentations non 5q SMA. An increased
awareness of these non-5q SMA-like patients will help to more rapid
diagnosis and provide more optimal disease management. Additionally,
this is a diagnosis that should be considered in the case of an infant
with rapidly progressive bulbar, axial and appendicular weakness,
adding to SMA, SMARD, and pontocerebellar hypoplasias which may
have similarly aggressive patterns of weakness. By increasing aware-
ness of these non-5q SMA-like patients, we can more rapidly diagnose
and provide optimal treatment to these patients.
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